Ratiopharm

Ratiopharm is a pharmaceutical brand operating under Teva Pharmaceutical Industries Ltd., an israeli multinational pharmaceutical company headquartered in Tel Aviv. The boycott of Ratiopharm is directly tied to the israeli nationality, corporate base, and massive financial contributions of its parent company, Teva Pharmaceutical, to the israeli state.

Core Boycott Reasons:

• israeli Origin & Headquarters: Teva Pharmaceutical Industries Ltd. is headquartered in Tel Aviv / Petah Tikva, israel, and stands as one of the largest generic drug manufacturers in the world, representing one of the cornerstone corporations of the israeli economy.
• $750 Million israeli Tax Agreement: In June 2024, Teva concluded a landmark $750 million agreement with the israel Tax Authority (ITA) to settle corporate tax liabilities, transferring vast tax revenues directly to the israeli treasury and state operations.
• Legal Action Against BDS Campaigners: Teva has engaged in aggressive legal actions against civil society activists and Palestine solidarity organizers in Europe (e.g., EuroPalestine in France) to suppress consumer boycott campaigns.
• Direct Capital Inflow to israel: Commercial revenues and profits generated by Ratiopharm flow directly into Teva's israeli corporate balance sheet, sustaining its corporate infrastructure in israel.

Consequently, Ratiopharm is subject to boycott due to its direct corporate ownership by Teva Pharmaceutical Industries. For complete documentation and SEC filing citations, please review the primary Teva Pharmaceutical boycott page.